Токсичность трабектединсодержащих комбинаций в терапии различных злокачественных новообразований
- Авторы: Черкасова М.В.1, Хохлова С.В.2, Лимарева С.В.2, Орел Н.Ф.1, Горбунова В.А.2, Поддубная И.В.1, Любимова Н.В.2
-
Учреждения:
- ГБОУ ДПО Российская медицинская академия последипломного образования Минздрава РФ, Москва
- ФГБУ РОНЦ им. Н.Н.Блохина РАМН, Москва
- Выпуск: Том 15, № 2 (2013)
- Страницы: 46-52
- Раздел: Статьи
- URL: https://journals.rcsi.science/1815-1434/article/view/26905
- ID: 26905
Цитировать
Полный текст
Аннотация
Ключевые слова
Полный текст
Открыть статью на сайте журналаОб авторах
Марина Валерьевна Черкасова
ГБОУ ДПО Российская медицинская академия последипломного образования Минздрава РФ, Москва
Email: m_cherkasova@mail.ru
аспирант каф. онкологии
Светлана Викторовна Хохлова
ФГБУ РОНЦ им. Н.Н.Блохина РАМН, Москваканд. мед. наук, ст. науч. сотр. отд-ния химиотерапии
Светлана Владимировна Лимарева
ФГБУ РОНЦ им. Н.Н.Блохина РАМН, Москваканд. мед. наук, науч. сотр. отд-ния химиотерапии
Надежда Федоровна Орел
ГБОУ ДПО Российская медицинская академия последипломного образования Минздрава РФ, Москвад-р мед. наук, вед. науч. сотр. отд-ния химиотерапии ФГБУ РОНЦ им. Н.Н.Блохина РАМН, проф. каф. онкологии ГБОУ ДПО РМАПО Минздрава РФ
Вера Андреевна Горбунова
ФГБУ РОНЦ им. Н.Н.Блохина РАМН, Москвад-р мед. наук, проф., зав. отд-нием химиотерапии
Ирина Владимировна Поддубная
ГБОУ ДПО Российская медицинская академия последипломного образования Минздрава РФ, Москвачл.-кор. РАМН, д-р мед. наук, проф., зав. каф. онкологии ГБОУ ДПО РМАПО
Нина Васильевна Любимова
ФГБУ РОНЦ им. Н.Н.Блохина РАМН, Москвад-р мед. наук, вед. науч. сотр. лаборатории клинической биохимии
Список литературы
- David-Cordonnier M.H, Gajate C, Olmea O et al. DNA and non - DNA targets in the mechanism of action of the antitumor drug trabectedin. Chem Biol 2005; 12: 1201–10.
- Valoti G, Nicoletti M.I, Pellegrino A et al. Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Clin Cancer Res 1998; 4: 1977–83.
- Hendriks H.R, Fiebig H.H, Giavazzi R et al. High antitumor activity of ET743 against human tumor xenografts from melanoma, non - small - cell lung and ovarian cancer. Ann Oncol 1999; 10: 1233–40.
- Cesne A, Yovine A, Blay J.Y et al. A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials. Invest New Drugs 2012; 30: 1193–202.
- Twelves C, Hoekman K, Bowman A et al. Phase I and pharmacokinetic study of Yondelis (ecteinascidin-743, ET-743) administreted as on infusion over 1h or 3h every 21 days in patients with solid tumors. Eur J Cancer 2003; 39: 1842–51.
- Mc Meekin S, del Campo J.M, Colombo N et al. Trabectedin in relapsed advanced ovarian cancer (ROC): A pooled analysis of three phase II studies. ASCO Meeting Abstr 2007; 25 (Suppl. 18): 5579.
- Sessa C, de Braud F, Perotti A et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol 2005; 20: 1867–74.
- Krasner C.N, Mc Meekin D.S, Chan S et al. A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum - based regimens. Br J Cancer 2007; 97 (12): 1618–24.
- Campo Del J.M, Roszak A, Bidzinski M et al. Phase II randomized study of trabectedin given as 2 different every 3 weeks dose schedules (1,5 mg/m2 24h or 1,3 mg/m2 3h) to patients with relapsed, platinum - sensitive, advanced ovarian cancer. Ann Oncol 2009; 20: 1794–802.
- Sessa C, Cresta S, Noberasco C et al. Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumors. Eur J Cancer 2009; 45: 2116–22.
- Sessa C, Gallerani E, Conte Del G et al. Phase I dose - finding study of trabectedin (T) in combination with cisplatin (C) in patients (pts) with advanced solid tumors. J Clin Oncol 29: 2011 (Suppl; abstr. 2517).
- Vidal L, Garcia-Martin M, Tan S et al. Phase I combination study of trabectedin and carboplatin in patients with advanced solid tumors. Ann Oncol 2010; 15 (Suppl. 3): 102–1.
- Gore L, Rivera E, Lavalee K et al. Phase I combination study of trabectedin (T) and capecitabine (C) in patients with advanced malignancies. J Clin Oncol 2006; 24 (Suppl. 18S): 2079.
- Messersmith W.A, Jimeno A, Ettinger D et al. Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors. Cancer Chemoter Pharmacol 2008; 63: 181–8.
- Sessa C, Perotti A, Noberasco C et al. Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer. Eur J Cancer 2009; 45 (7): 1153–61.
- Monk B.J, Sill M, Walker J.L et al. Activity of docetaxel plus trabectedin in reccurent or persistent ovarian and primary peritoneal cancer: A phase II study of the Gynecologic Oncology Group (GOG). J Clin Oncol 2010; 28 (Suppl. 15): 5046.
- Papadopoulos K.P, Chu Q, Patnaik A et al. Phase I pharmacokinetics (PK) study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors. J Clin Oncol 2006. ASCO Ann Meeting Proceedings (part I) 2006; 24 (18): 2029.
- Poveda A, Kaye S.B, Herzog T et al. Correlation RNA expression of DNA repair genes with clinical outcomes of advanced ovarian cancer (OC) pts treated with pegylated liposomal doxorubicin (PLD) vs trabectedin (T) + PLD in the ET-743-OVA-301 clinical trial. Eur J Cancer Suppl 2009; 7: 451.
- Romero I, Colombo N, Kaye S.B et al. Tolerability of long - term use of trabectedin (Tr) in combination with pegylated liposomal doxorubicin (PLD) in patients (pts) with relapsed ovarian cancer (ROC). J Clin Oncol 2010; 28: 15. Abstr. 5121.
- Monk B.J, Dalton H, Benjamin I et al. Trabectedin as a new chemotherapy option in the treatment of relapsed platinum sensitive ovarian cancer. Curr Pharm Des 2012; 18 (25): 3754–69.
- Grosso F, D´Incalci M, Cartoafa M et al. A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin. Cancer Chemother Pharmacol 2012; 69 (6): 1557–65.
- Chatzizisis Y.S, Misirli G, Hatzitolios A.I et al. The syndrome of rhabdomyolysis: complications and treatment. Eur J Intern Med 2008; 19: 568–74.
- Khan F.Y. Rhabdomyolysis: a review of the literature. Neth J Med 2009; 67: 272–83.
- Cesne Le A, Yovine A, Blay J.Y et al. A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials. Invest New Drugs 2012; 30: 1193–202.
- Cervellin G, Comelii I, Lippi G. Rhabdomyolysis: historical background, clinical, diagnostic and therapeutic features. Clin Chem Lab Med 2010; 48 (6): 749–56.